MULTI-CENTER RANDOMIZED STUDY CONTROLLED WITH DOUBLE-BLIND PLACEBO OF 3 ARMS OF PHASE 3 TO EVALUATE THE SAFETY AND EFFICACY OF THE ADMINISTRATION OF TIFACOGIN (RECOMBINANT INHIBITOR OF THE TISSUE FACTOR´S ROUTE) IN SUBJECTS WITH PNEUMONIA ACQUIRED IN THE SEVERE COMMUNITY

Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2004
This article has no abstract
Epistemonikos ID: c74180f60f0a3063509c6c685bae28cae2ef0403
First added on: Apr 16, 2025